Literature DB >> 1698567

Enhancement of anthracycline and alkylator cytotoxicity by ethacrynic acid in primary cultures of human tissues.

R A Nagourney1, J C Messenger, D H Kern, L M Weisenthal.   

Abstract

Ethacrynic acid [2,3-dichloro-4-(2-methylene-1-oxobutyl)phenoxyl] acetic acid, is a water-soluble diuretic agent that has been shown to potentiate the in vitro cytotoxicity of chemotherapeutic agents in established cell lines. We used the differential staining cytotoxicity (DiSC) assay to determine whether ethacrynic acid at 1 and 3.3 microM would potentiate the cytotoxicity of nitrogen mustard and/or doxorubicin in primary cultures of hematologic neoplasms from heavily pretreated patients and in normal peripheral blood lymphocytes. At 3.3 microM, ethacrynic acid was toxic to 8 of 24 (33%) tumor specimens studied. In subsequent studies, ethacrynic acid at 1 microM was toxic to only 2 of 54 (4%) tumor specimens. Significant enhancement for doxorubicin or nitrogen mustard was confined to lymphatic malignancies and to normal peripheral blood lymphocytes. Interspecimen variability was observed, with no enhancement in most individual specimens, 2-fold enhancement in some specimens, and 4-fold enhancement in occasional specimens. Clinical trials will be required to determine whether the observed in vitro activity for ethacrynic acid is associated with clinical benefit in unselected or assay-selected patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1698567     DOI: 10.1007/bf02897285

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  28 in total

1.  Laboratory detection of primary and acquired drug resistance in human lymphatic neoplasms.

Authors:  L M Weisenthal; P L Dill; J Z Finklestein; T E Duarte; J A Baker; E M Moran
Journal:  Cancer Treat Rep       Date:  1986-11

2.  Semi-micro adaptation of a 4-day differential staining cytotoxicity (DiSC) assay for determining the in-vitro chemosensitivity of haematological malignancies.

Authors:  M C Bird; A G Bosanquet; S Forskitt; E D Gilby
Journal:  Leuk Res       Date:  1986       Impact factor: 3.156

3.  Antioxidant enzymes in lymphocytes from normal subjects and patients with chronic lymphocytic leukaemia: increased glutathione peroxidase activity in CLL B lymphocytes.

Authors:  C M Farber; D N Kanganis; L F Liebes; R Silber
Journal:  Br J Haematol       Date:  1989-05       Impact factor: 6.998

4.  Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells.

Authors:  K Dano
Journal:  Biochim Biophys Acta       Date:  1973-10-25

5.  Dechlorination of L-phenylalanine mustard by sensitive and resistant tumor cells and its relationship to intracellular glutathione content.

Authors:  K Suzukake; B P Vistica; D T Vistica
Journal:  Biochem Pharmacol       Date:  1983-01-01       Impact factor: 5.858

6.  Role of glutathione and dependent enzymes in anthracycline-resistant HL60/AR cells.

Authors:  J Lutzky; M B Astor; R N Taub; M A Baker; K Bhalla; J E Gervasoni; M Rosado; V Stewart; S Krishna; A A Hindenburg
Journal:  Cancer Res       Date:  1989-08-01       Impact factor: 12.701

7.  Anthracycline antibiotic pharmacology and metabolism.

Authors:  N R Bachur
Journal:  Cancer Treat Rep       Date:  1979-05

8.  Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines.

Authors:  K D Tew; A M Bomber; S J Hoffman
Journal:  Cancer Res       Date:  1988-07-01       Impact factor: 12.701

9.  Vinblastine photoaffinity labeling of a high molecular weight surface membrane glycoprotein specific for multidrug-resistant cells.

Authors:  A R Safa; C J Glover; M B Meyers; J L Biedler; R L Felsted
Journal:  J Biol Chem       Date:  1986-05-15       Impact factor: 5.157

10.  Glutathione S-transferase isoenzymes and glutathione peroxidase activity in normal and tumour samples from human lung.

Authors:  J Carmichael; L M Forrester; A D Lewis; J D Hayes; P C Hayes; C R Wolf
Journal:  Carcinogenesis       Date:  1988-09       Impact factor: 4.944

View more
  3 in total

1.  Wnt/ß-catenin: a new therapeutic approach to acute myeloid leukemia.

Authors:  Y Kim; S Thanendrarajan; I G H Schmidt-Wolf
Journal:  Leuk Res Treatment       Date:  2011-12-01

Review 2.  Modulation of cis-diamminedichloroplatinum(II) resistance: a review.

Authors:  H Timmer-Bosscha; N H Mulder; E G de Vries
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

3.  A study of ethacrynic acid as a potential modifier of melphalan and cisplatin sensitivity in human lung cancer parental and drug-resistant cell lines.

Authors:  T Rhodes; P R Twentyman
Journal:  Br J Cancer       Date:  1992-05       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.